Ciprofol suppresses proliferation, invasion and migration of human pancreatic cancer cells

Area of Science:

• Oncology
• Anesthesiology
• Molecular Biology

Background:

• Pancreatic cancer (PC) presents a high mortality rate and poor prognosis.
• Perioperative factors, including anesthetics, may influence cancer progression.
• Ciprofol is a recently developed intravenous anesthetic.

Purpose of the Study:

• To investigate the effects of ciprofol on pancreatic cancer cells.
• To explore the molecular pathways through which ciprofol influences PC.
• To identify potential therapeutic targets related to ciprofol's action in PC.

Main Methods:

• Cell proliferation, migration, invasion, and apoptosis assays (MTT, Transwell, flow cytometry).
• RNA-sequencing (RNA-seq) to identify differentially expressed genes (DEGs) and construct protein-protein interaction networks.
• Quantitative real-time PCR to confirm MMP1 gene expression and survival analysis.

Main Results:

• Ciprofol significantly suppressed proliferation, migration, and invasion of PANC-1 cells in a dose- and time-dependent manner.
• RNA-seq identified 929 DEGs, with 5 hub genes selected for further analysis.
• MMP1 gene expression was confirmed, suggesting its role in PC carcinogenesis and potential link to ciprofol's effects; hsa-miR-330-5p was identified as a target miRNA of MMP1.

Conclusions:

• Ciprofol exhibits anti-cancer properties against pancreatic cancer cells by inhibiting aggressiveness.
• MMP1 is implicated in PC development and may be a key mediator of ciprofol's therapeutic potential.
• Further research into ciprofol and MMP1 could lead to novel therapeutic strategies for pancreatic cancer.